webinar register page

Coffee & Conversation with IF's Research Partners


Mar 31, 2020 09:13 AM

Webinar logo
* Required information


Dr. Stephen Schoenberger
Center Head; Professor, Laboratory of Cellular Immunology; Director of Translational Science @La Jolla Institute for Immunology; San Diego Center for Precision Immunotherapy
Dr. Schoenberger is Center Head and Professor at the La Jolla Institute for Immunology in the Laboratory of Cellular Immunology and Co-Director of the San Diego Center for Precision Immunotherapy, as well Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UCSD Moores Cancer Center. He received his Ph.D. in Microbiology and Molecular Genetics from UCLA in 1993 and completed postdoctoral training in Immunohematology and Tumor Immunology at the University of Leiden in The Netherlands. Dr. Schoenberger was appointed to LJI’s faculty in 1998 as an Assistant Professor, was promoted to Associate Professor in 2002, gained Tenure in 2005, and became a Professor in 2007. He is a recipient of Scholar Awards from both the American Cancer Society and the Leukemia and Lymphoma Society, and is on the editorial advisory board of the Journal of Experimental Medicine. Learn more about Dr. Schoenberger's work at https://www.lji.org/faculty-research/labs/schoenberger/.
Dr. Ezra Cohen
Chief of the Division of Hematology‐Oncology and Associate Director, Translational Science; Co-Director @UC San Diego Moores Cancer Center; San Diego Center for Precision Immunotherapy
Ezra Cohen, MD, is Chief of the Division of Hematology‐Oncology, and co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He recently served as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease. More: //medschool.ucsd.edu/research/moores/about/leadership/directors-office/Pages/translational-science.aspx